# US 2021/0275510 A1 · Pyridine derivatives substituted by heterocyclic ring and amino group

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275510 A1
- Document ID: US20210275510A1
- Status: Published application
- Kind: A1
- Application number: 17/253,885
- Filed: 2019-06-24
- Published: 2021-09-09
- Earliest claimed: 2018-06-25
- Assignees: Amplyx Pharmaceuticals, Inc.
- Applicants: Amplyx Pharmaceuticals, Inc.
- Inventors: Andrei W. KONRADI; Jonathan A. COVEL; Michael GREY
- Web page: https://patentgrep.com/patent/US20210275510A1

## CPC

- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/4174: Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61P 31/10: Antimycotics
- C07B 59/004: {Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium}
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/14: containing three or more hetero rings
- C07H 15/26: Acyclic or carbocyclic radicals, substituted by hetero rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

Described herein are pyridine derivatives substituted by heterocycle and amino groups and pharmaceutical compositions comprising said compounds. The disclosed compounds are antifungal agents. The subject compounds and compositions are useful for the treatment of fungal diseases and infections.

## Claims

### Claim 1

A compound of structural Formula (II), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof:
wherein:
one of X1 and Y is nitrogen while the other is nitrogen or oxygen;
W is N or N—R15;
A is substituted or unsubstituted phenyl or substituted or unsubstituted pyridinyl;
Z is a bond, —(CH2)z1—, —O—, —S—, —CH2O—, —OCH2—, —NH—, —CH2NH—, —NHCH2—, —CH2S—, or —SCH2—;
z1 is 1 or 2;
R1 is hydrogen, halogen, —NR1BR1C, —C(O)NR1BR1C, —OR1A, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl;
R2 is hydrogen or halogen;
R3 is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R13 is —SOn13R13A, —SOv13NR13BR13C, —C(O)R13D, —C(S)R13D, —C(O)X2R13C, —C(S)OR13D, —C(S)NR13BR13C, substituted alkyl, substituted or unsubstituted heteroalkyl; or R13 together with the nitrogen to which it is attached forms an amino acid, a dipeptide, or a tripeptide;
X2 is —O—, —S—, or —NR13B;
R14 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R15 is —SOn15R15A, —SOv15NR15BR15C, —C(O)R15D, —C(S)R15D, —C(O)OR15D, —C(S)OR15D, —C(O)SR15D, —C(O)NR15BR15C, —C(S)NR15BR15C, —CH2OPO3H2, —CH2OSO3H, —CH2OPO3H−, —CH2OSO3−, —C(O)CH2X3, or substituted or unsubstituted heteroalkyl;
X3 is —F, —Cl, —Br, —I, —CHF2, —CHCl2, —CHBr2, —CHI2, —CF3, —CCl3, —CBr3, —CI3, or —NOz;
n13 and n15 are independently an integer from 0 to 4;
v13 and v15 are independently 1 or 2; and
R1A, R1B, R1C, R13A, R13B, R13C, R13D, R15A, R15B, R15C, and R15D are independently hydrogen, halogen, —CF3, —CCl3, —CBr3, —CI3, —COOH, —CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; or
R13B and R13C or R15B and R15C substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein W is N+—R15.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or 2, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein R15 is substituted or unsubstituted heteroalkyl.

### Claim 4 (depends on 1, 2)

The compound of claim 1 or 2, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein R15 is —CH2OPO3H2, —CH2OPO3H−, —CH2OSO3H−, or —CH2OSO3−.

### Claim 5 (depends on 1, 2)

The compound of claim 1 or 2, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein R15 is —C(O)CH2X3.

### Claim 6 (depends on 1, 2, 3)

The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein R15 is:
Ra is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a side chain of a natural amino acid; and
Rb and Rc are independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

### Claim 7 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein W is N.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein R13 is —C(O)R13D or —C(O)X2R13C.

### Claim 9 (depends on 8)

The compound of claim 8, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein:
R13 is —C(O)X2R13C;
X2 is —O—; and
R13C is substituted or unsubstituted phenyl.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein the compound has structural Formula (I):

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 10)

The compound of any one of claims 1-8 or 10, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein R13D is substituted alkyl substituted or unsubstituted heteroalkyl, or substituted or unsubstituted heterocycloalkyl.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 10, 11)

The compound of any one of claims 1-8 or 10-11, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein R13D is —SCH3, —OCH2CH3, —SCH2CH3,
wherein:
Ra and Rd are independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a side chain of a natural amino acid; and
Rb and Rc are independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

### Claim 13 (depends on 12)

The compound of claim 12, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein:
Ra and Rd are independently hydrogen, methyl, isopropyl, 1-methylpropyl, 2-methylpropyl, 1-hydroxyethyl, or a side chain of a natural amino acid;
Rb is hydrogen, ethyl, isopropyl, an amino acid, or a dipeptide; and
Rc is independently hydrogen, —F, —CF3, —OH, or

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 10, 11)

The compound of any one of claims 1-8 or 10-11, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein R13D is —CH2Cl.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 10, 11)

The compound of any one of claims 1-8 or 10-11, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein R13D is:

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 10, 11)

The compound of any one of claims 1-8 or 10-11, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein R13D is:
wherein:
Rb is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 10, 11)

The compound of any one of claims 1-8 or 10-11, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein R13D is:
and
wherein:
Ra is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a side chain on a natural amino acid; and
Rb and Rc are independently substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 10, 11)

The compound of any one of claims 1-8 or 10-11, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein R13D is:
wherein:
Ra and Rd are independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a side chain on a natural amino acid.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 10, 11)

The compound of any one of claims 1-8 or 10-11, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein R13D is —SCH3, —OCH2CH3, —SCH2CH3,

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 10, 11)

The compound of any one of claims 1-8 or 10-11, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein R13D is:
wherein:
Ra and Rd are independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a side chain on a natural amino acid; and
Rb is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein R13 together with the nitrogen to which it is attached forms an amino acid, a dipeptide, or a tripeptide.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 21)

The compound of any one of claims 1-7 or 21 or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein R13 is:

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The compound of any one of claims 1-22, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein one of X1 and Y is a nitrogen atom and the other is an oxygen atom.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The compound of any one of claims 1-23, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein a partial structure represented by
in Formulas (I) and/or (II) is

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The compound of any one of claims 1-24, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein Z is —O—, —CH2O—, or —OCH2—.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The compound of any one of claims 1-25, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein R3 is unsubstituted pyridine.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The compound of any one of claims 1-26, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein A is unsubstituted phenyl.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The compound of any one of claims 1-27, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein R1 and R2 are hydrogen.

### Claim 29 (depends on 1, 7, 8)

The compound of any one of claims 1, 7, 8, or 10-20, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein the compound has structural Formula (Ia):

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound of any one of claims 1-7, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein R13 is —C(O)X2R13C.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 30)

The compound of any one of claims 1-9 or 30 or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein the compound has structural Formula (Ib):

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 31)

The compound of claim 1-9 or 31, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein R13C is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroalkyl.

### Claim 33 (depends on 30, 31, 32)

The compound of claim 30-32, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein a partial structure represented by
in Formulas (II) and/or (Ib) is

### Claim 34 (depends on 30, 31, 32, 33)

The compound of any one of claims 30-33, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein Z is —O—, —CH2O—, or —OCH2—.

### Claim 35 (depends on 30, 31, 32, 33, 34)

The compound of any one of claims 30-34, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein R3 is unsubstituted pyridine.

### Claim 36 (depends on 30, 31, 32, 33, 34, 35)

The compound of any one of claims 30-35, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein A is unsubstituted phenyl.

### Claim 37 (depends on 30, 31, 32, 33, 34, 35, 36)

The compound of any one of claims 30-36, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein R1 and R2 are hydrogen.

### Claim 38 (depends on 1, 7, 8, 9)

The compound of any one of claims 1, 7-9, or 30-32, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, wherein the compound has structural Formula (Ibb):

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

A pharmaceutical composition comprising the compound of any one of claims 1-38, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and at least one pharmaceutically acceptable carrier.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

A method of treating a fungal disease or infection, comprising administering to a subject in need thereof a therapeutically effective amount of the compound of any one of claims 1-38, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, or the pharmaceutical composition of claim 39.

### Claim 41 (depends on 40)

The method of claim 40, wherein the fungal disease or infection is caused by a Cryptococcus, Aspergillus, Candida, Fusarium, or Scedosporium fungus or a fungus from the Mucorales order.

### Claim 42 (depends on 40, 41)

The method of claim 40 or 41, wherein the fungal disease or infection is azole-resistant and/or echinocandin-resistant.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 40-42, further comprising administering at least one antifungal agent in combination with the compound of any one of claims 1-38, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, or the pharmaceutical composition of claim 39.

### Claim 44 (depends on 43)

The method of claim 43, wherein the at least one antifungal agent is an azole, an echinocandin, amphotericin B deoxycholate, amphotericin B cochleate, 5-fluorocytosine, terbinafine, griseofulvin, VL-2397, ibrexafungerp, orotomide F901318, or combinations thereof.

### Claim 45 (depends on 44)

The method of claim 44, wherein the azole is ketoconazole, fluconazole, posaconazole, itraconazole, voriconazole, isavuconazole, or miconazole.

### Claim 46 (depends on 44)

The method of claim 44, wherein the echinocandin is caspofungin, anidulafimgin, micafungin, or rezafungin.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 43, 44, 45, 46)

The method of any one of claims 43-46, wherein the compound of any one of claims 1-38, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, or the pharmaceutical composition of claim 39, and the antifungal agent are administered simultaneously, approximately simultaneously, or sequentially, in any order.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 47)

The method of claim 47, wherein the compound of any one of claims 1-38, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, or the pharmaceutical composition of claim 39, and the antifungal agent are administered simultaneously or approximately simultaneously.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 47)

The method of claim 47, wherein the compound of any one of claims 1-38, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, or the pharmaceutical composition of claim 39, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the antifungal agent are administered sequentially.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 49)

The method of claim 49, wherein the compound of any one of claims 1-38, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, or the pharmaceutical composition of claim 39, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, is administered before the at least one antifungal agent.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 49)

The method of claim 49, wherein the compound of any one of claims 1-38, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, or the pharmaceutical composition of claim 39, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, is administered after the at least one antifungal agent.

### Claim 52 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The method of any one of claims 40-51, wherein the subject has reduced colony counts of fungi in the lungs after administration of the pharmaceutical composition.
